Navigation Links
Kentucky team inhibits Alzheimer's biomarkers in animal model by targeting astrocytes
Date:12/11/2012

LEXINGTON, Ky. (Dec. 10, 2012) A research team composed of University of Kentucky researchers has published a paper which provides the first direct evidence that activated astrocytes could play a harmful role in Alzheimer's disease. The UK Sanders-Brown Center on Aging has also received significant new National Institutes of Health (NIH) funding to further this line of study.

Chris Norris, an associate professor in the UK College of Medicine Department of Molecular and Biomedical Pharmacology, as well as a member of the faculty at the UK Sanders-Brown Center on Aging, is the senior author on a paper published recently in the Journal of Neuroscience, entitled "Targeting astrocytes to ameliorate neurologic changes in a mouse model of Alzheimer's disease." The first author on the article, Jennifer L. Furman, was a graduate student in the Norris laboratory during completion of the study.

The astrocyte is a very abundant non-neuronal cell type that performs absolutely critical functions for maintaining healthy nervous tissue. However, in neurodegenerative diseases, like Alzheimer's disease, many astrocytes exhibit clear physical changes often referred to as "astrocyte activation." The appearance of activated astrocytes at very early stages of Alzheimer's has led to the idea that astrocytes contribute to the emergence and/or maintenance of other pathological markers of the disease, including synaptic dysfunction, neuroinflammation and accumulation of amyloid plaques.

Using an animal model, researchers directly modulated the activation state of hippocampal astrocytes using a form of gene therapy.

Mice received the gene therapy at a very young age, before the development of extensive amyloid plaque pathology, and were assessed 10 months later on a variety of Alzheimer's biomarkers.

The research team found that inhibition of astrocyte activation blunted the activation of microglia (a cell that mediates neuroinflammation), reduced toxic amyloid levels, improved synaptic function and plasticity, and preserved cognitive function.

Norris and collaborators suggest that similar astrocyte-based approaches could be developed to treat humans suffering from Alzheimer's disease, or possibly other neurodegenerative diseases. This study provides proof of principle that therapeutically targeting astrocytes can be beneficial.

Norris has been named the principal investigator on a new NIH award totaling $1,498,423 over a period of 5 years, to continue this line of research on Alzheimer's disease.


'/>"/>

Contact: Allison Elliott
allison.elliott@uky.edu
University of Kentucky
Source:Eurekalert

Related medicine news :

1. Kentucky study finds common drug increases deaths in atrial fibrillation patients
2. InsuranceCalculator.net Now Provides Competitive Car Insurance Quotes To Kentucky Drivers
3. Feola, at University of Kentucky, receives NIH grant to study cystic fibrosis
4. New monoclonal antibody inhibits tumor growth in advanced solid tumors in phase I clinical trial
5. Molecule found that inhibits recovery from stroke
6. Bloodstream scavenger inhibits clotting without increased bleeding
7. Metabolic biomarkers for preventive molecular medicine
8. Tracking down smallest biomarkers
9. Biomarkers of behavior, therapeutic targets for adult B-acute lymphoblastic leukemia identified
10. US Army: Pre-injury cartilage biomarkers associated with subsequent ACL injuries
11. Using biomarkers to identify and treat schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... ... Only two months after the official release of The Private Collection – Edition 2017 ... initiated a second print-run of its lavish luxury travel coffee table book. , ... in at more than six kilos, retails at EUR 1,000 per copy and is ...
(Date:2/24/2017)... ... February 24, 2017 , ... The Smart Machine Age is here, ... predict that 47 percent of all jobs in the United States may be taken ... The day of the aggressive know-it-all who steamrolls over colleagues is drawing to a ...
(Date:2/24/2017)... Australia (PRWEB) , ... February 24, 2017 , ... The ... AU) offers Erik Schanssema ’s true account of his paramedic experiences. Schanssema describes ... stress disorder and his attempts to overcome them. , Schanssema, initially unsure of ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... The International ... 7th annual “Imagine Me Beyond What You See” body image mannequin art competition. Selected ... will be showcased and the winner revealed at the 31st annual iaedp Symposium, March ...
(Date:2/24/2017)... ... February 24, 2017 , ... ... Senior International Elite division on February 12th. Ms. Esparza qualified into this ... elite qualifier competition held in Las Vegas, Nevada. Frida is one of approximately ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... , Australie, le 24 février 2017 ITL Limited, ( ... diversifiée innovante, est ravie d,annoncer les excellents résultats semestriels ... période précédente correspondante. Une présentation complète « Résultats et mise ... consultée ici . Faits marquants ... 2,12 millions $ (Déc. 2015 : 1,04 million $ ; en hausse de 104 %) ...
(Date:2/24/2017)... 23, 2017 Non-alcoholic steatohepataitis (NASH) ... various drugs being developed for the treatment ... drugs that are in various phases of ... focuses on novel pharmacologic drugs & regenerative ... therapies, recombinant proteins and RNA-based therapeutics, but ...
(Date:2/24/2017)... , Feb. 24, 2017  Xynomic Pharmaceuticals, Inc., an ... that it has acquired exclusive worldwide rights to ... innovative HDAC inhibitor targeting hematological and solid tumors. ... Phase 1 and 2 clinical trials of Abexinostat ... have already been completed, demonstrating that Abexinostat ...
Breaking Medicine Technology: